N
Nicolas Mounier
Researcher at Centre Hospitalier Universitaire de Nice
Publications - 198
Citations - 10465
Nicolas Mounier is an academic researcher from Centre Hospitalier Universitaire de Nice. The author has contributed to research in topics: Rituximab & Diffuse large B-cell lymphoma. The author has an hindex of 51, co-authored 197 publications receiving 9352 citations.
Papers
More filters
Journal ArticleDOI
Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients
B. Coiffier,P. Feugier,Nicolas Mounier,P. Franchi-Rezgui,E. Van Den Neste,Margaret Macro,Corinne Haioun,Catherine Sebban,Dominique Bordessoule,H. Tilly +9 more
TL;DR: The 7-year follow-up of the prospective randomized study LNH-98.5 is presented, showing the same difference as reported before with a large difference in survival curves.
Journal ArticleDOI
GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin's B lymphomas via NF-κB-dependent induction of HIF-1α.
Johanna Chiche,S Pommier,Marie Bénéteau,Laura Mondragón,Ophélie Meynet,Barbara Zunino,A Mouchotte,E Verhoeyen,M Guyot,Gilles Pagès,Nicolas Mounier,Véronique Imbert,Pascal Colosetti,Diogo Gonçalvès,Sandrine Marchetti,Josette Brière,Michel Carles,Catherine Thieblemont,J-E Ricci +18 more
TL;DR: Elevated expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression promotes NF-κB-dependent induction of HIF-1α and has a key role in lymphoma vascularization and aggressiveness.
Journal ArticleDOI
Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma.
Nicolas Mounier,Josette Brière,Christian Gisselbrecht,Felix Reyes,Philippe Gaulard,Bertrand Coiffier,Groupe d'Etude des Lymphomes de l'Adulte +6 more
TL;DR: Rituximab plus CHOP (R-CHOP) has been proven to increase overall survival in aggressive bcl-2-positive lymphoma patients and the long-term impact of this treatment in patients from a GELA trial was studied.
Journal ArticleDOI
Mobile applications in oncology: is it possible for patients and healthcare professionals to easily identify relevant tools?
TL;DR: There is a need to enforce independent review of mhealth applications in oncology and the economic model could be questioned and the source of funding should be clarified, while patients and healthcare professionals should remain cautious about applications’ contents.
Journal ArticleDOI
R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study
Christian Gisselbrecht,B. Glass,Nicolas Mounier,Devinder Gill,Dc Linch,Marek Trneny,André Bosly,Ofer Shpilberg,Nicolas Ketterer,Craig H. Moskowitz,Norbert Schmitz +10 more
TL;DR: Early relapses/ refractory pts to upfront rituximab-based chemotherapy have a poor response rate and prognosis, and longer follow up is necessary to evaluate the second randomization.